PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2545578-4 1989 The IC50 values of MK-421 and MK-422 against ACE were 2,000 nM and 3.5 nM, respectively. Enalaprilat 30-36 angiotensin I converting enzyme Rattus norvegicus 45-48 2821209-6 1987 Enalaprilat or captopril administered to rats caused a decrease in mean arterial blood pressure that lasted for over 24 h. In mesenteric preparations taken from animals 24 h after treatment with ACE inhibitors, kininase activity was inhibited whereas converting activity was unchanged. Enalaprilat 0-11 angiotensin I converting enzyme Rattus norvegicus 195-198 2822902-5 1987 Finally, the effect of pH in the perfusing solution on ACE inhibition by enalaprilat was studied. Enalaprilat 73-84 angiotensin I converting enzyme Rattus norvegicus 55-58 3005826-8 1986 The affinity of ACE for both [3H] captopril and enalaprilat is greater at 37 degrees than at 0 degree, demonstrating that these interactions are entropically driven, perhaps by an isomerization of the enzyme molecule. Enalaprilat 48-59 angiotensin I converting enzyme Rattus norvegicus 16-19 3029219-1 1986 Angiotensin converting enzyme (ACE) was measured in rat plasma and tissues by analysis of the binding of the radio-inhibitor 125I-MK351A, a tyrosyl derivative of enalaprilic acid. Enalaprilat 162-178 angiotensin I converting enzyme Rattus norvegicus 0-29 3029219-1 1986 Angiotensin converting enzyme (ACE) was measured in rat plasma and tissues by analysis of the binding of the radio-inhibitor 125I-MK351A, a tyrosyl derivative of enalaprilic acid. Enalaprilat 162-178 angiotensin I converting enzyme Rattus norvegicus 31-34 2982830-10 1985 The formation of YGG, YGGF, and YGGFM by synaptic membranes could be stimulated 3-fold by the addition of 30 mM NaCl and inhibited by MK-422, an ACE inhibitor, with an IC50 of 3 nM. Enalaprilat 134-140 angiotensin I converting enzyme Rattus norvegicus 145-148 25663023-0 2015 Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat. Enalaprilat 64-75 angiotensin I converting enzyme Rattus norvegicus 45-48 6295819-2 1983 The parent diacid (MK-422) N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro of MK-421 inhibited hog plasma ACE with an I50 of 1.2 nM. Enalaprilat 19-25 angiotensin I converting enzyme Rattus norvegicus 103-106 6295819-4 1983 However, both enalapril and MK-422 were potent inhibitors of ACE by the i.v. Enalaprilat 28-34 angiotensin I converting enzyme Rattus norvegicus 61-64 6175573-7 1982 We conclude that captopril and MK-421 diacid decreases vascular reactivity in the rat isolated kidney by a mechanism independent of ACE inhibition and unrelated to a prostaglandin-dependent vascular mechanism. Enalaprilat 31-44 angiotensin I converting enzyme Rattus norvegicus 132-135 32494933-7 2020 These consistent changes were also observed by treating the H19-7 fetal hippocampal cell line with dexamethasone and were reversed by GR inhibitor (RU486) and ACE inhibitor (enalaprilat). Enalaprilat 174-185 angiotensin I converting enzyme Rattus norvegicus 159-162 26793104-8 2015 These effects were potentiated ~15-fold by the angiotensin converting enzyme (ACE) inhibitor, enalaprilat, but extensively inhibited by icatibant (a B2R antagonist) and not influenced by the Arg-carboxypeptidase (CP) inhibitor (Plummer"s inhibitor). Enalaprilat 94-105 angiotensin I converting enzyme Rattus norvegicus 47-76 26793104-8 2015 These effects were potentiated ~15-fold by the angiotensin converting enzyme (ACE) inhibitor, enalaprilat, but extensively inhibited by icatibant (a B2R antagonist) and not influenced by the Arg-carboxypeptidase (CP) inhibitor (Plummer"s inhibitor). Enalaprilat 94-105 angiotensin I converting enzyme Rattus norvegicus 78-81 20048199-3 2010 We investigated the hypothesis that the acute administration of drugs to inhibit reactive oxygen species (Tempol), angiotensin II type 1 receptors (candesartan), or angiotensin-converting enzyme (enalaprilat) lowers mean arterial pressure and increases kidney blood flow and oxygenation in the clipped kidney of chronic 2K,1C rats in contrast to sham controls. Enalaprilat 196-207 angiotensin I converting enzyme Rattus norvegicus 165-194 20156432-5 2010 In rat mesenteric arteries, treatment of the vessels with an ACE inhibitor (enalaprilat) or angiotensin II type 1 receptor antagonist (candesartan) reduced PVAT-mediated potentiation of EFS-induced contraction. Enalaprilat 76-87 angiotensin I converting enzyme Rattus norvegicus 61-64 24342267-3 2014 Rats underwent subcutaneous infusions of ANG II or saline and bilateral PVN infusions of ACE inhibitor enalaprilat (ENL, 2.5mug/h) or vehicle for 4weeks. Enalaprilat 103-114 angiotensin I converting enzyme Rattus norvegicus 89-92 18329669-6 2008 The presence of angiotensin I-converting enzyme (ACE) inhibitor (50 nM enalaprilat) did not affect the WH-induced vasodilating effect, though WH showed a slight ACE inhibitory activity (IC50: 93 microM). Enalaprilat 71-82 angiotensin I converting enzyme Rattus norvegicus 49-52 19481149-2 2009 Here we investigated RAS signaling in retinas explanted from adult rats exposed for 48 h to high glucose (HG), with or without the Angiotensin Converting Enzyme inhibitor enalaprilat, which blocks RAS. Enalaprilat 171-182 angiotensin I converting enzyme Rattus norvegicus 131-160 17218981-6 2006 The angiotensin-converting enzyme (ACE) inhibitor enalaprilat enhanced responses to BK and the BK analog HT-BK without altering responses to PA-BK and inhibited responses to Ang I. Enalaprilat 50-61 angiotensin I converting enzyme Rattus norvegicus 4-33 18093879-8 2008 HgCl2 increased the angiotensin converting enzyme (ACE) activity explaining the result obtained with enalaprilate. Enalaprilat 101-113 angiotensin I converting enzyme Rattus norvegicus 20-49 18093879-8 2008 HgCl2 increased the angiotensin converting enzyme (ACE) activity explaining the result obtained with enalaprilate. Enalaprilat 101-113 angiotensin I converting enzyme Rattus norvegicus 51-54 17523052-4 2007 This cleavage could be inhibited by EDTA and the ACE inhibitor, enalaprilat, the de-esterified acid derivative of enalapril. Enalaprilat 64-75 angiotensin I converting enzyme Rattus norvegicus 49-52 17218981-6 2006 The angiotensin-converting enzyme (ACE) inhibitor enalaprilat enhanced responses to BK and the BK analog HT-BK without altering responses to PA-BK and inhibited responses to Ang I. Enalaprilat 50-61 angiotensin I converting enzyme Rattus norvegicus 35-38 17218981-11 2006 These data suggest that ACE inhibitor-potentiated responses to BK are not mediated by an A-779-sensitive mechanism and are consistent with the hypothesis that enalaprilat-induced BK potentiation is due to decreased BK inactivation. Enalaprilat 159-170 angiotensin I converting enzyme Rattus norvegicus 24-27 15992826-6 2005 Parallel groups were treated with the ACE inhibitor Enalaprilat (200 mg/kg/day). Enalaprilat 52-63 angiotensin I converting enzyme Rattus norvegicus 38-41 15992826-12 2005 Enalaprilat significantly decreased renal ACE activity in ANG II-treated rats, compared to ANG II alone (11.4 +/- 1.0 versus 59.2 +/- 11.9 units/mg protein; P < 0.001). Enalaprilat 0-11 angiotensin I converting enzyme Rattus norvegicus 42-45 12845221-11 2003 Administration of the ACE inhibitor, enalaprilat at the beginning of the experimental period, completely abrogated this decline and protected pO(2) levels throughout this period with no effect on blood pressure or renal blood flow. Enalaprilat 37-48 angiotensin I converting enzyme Rattus norvegicus 22-25 12191964-11 2002 These results indicate that addition of AngI in the interstitial compartment leads to low but significant conversion to AngII via ACE activity (blocked by enalaprilat). Enalaprilat 155-166 angiotensin I converting enzyme Rattus norvegicus 130-133 12191964-2 2002 This study was performed to determine changes in RIF AngI and AngII concentrations during interstitial administration of ACE inhibitors (enalaprilat and perindoprilat). Enalaprilat 137-148 angiotensin I converting enzyme Rattus norvegicus 121-124 10881050-5 2000 The specificity of the assay was demonstrated by the inhibition of ACE activity with 3 microM enalaprilat (MK-422). Enalaprilat 94-105 angiotensin I converting enzyme Rattus norvegicus 67-70 11342966-0 2001 The bladder angiotensin system in female rats: response to infusions of angiotensin I and the angiotensin converting enzyme inhibitor enalaprilat. Enalaprilat 134-145 angiotensin I converting enzyme Rattus norvegicus 94-123 11545137-2 2001 We examined whether the ACE inhibitor, enalaprilat (EN), improves intracellular sodium homeostasis during myocardial ischemia and the relationship of this effect to bradykinin. Enalaprilat 39-50 angiotensin I converting enzyme Rattus norvegicus 24-27 11139436-4 2000 ACE inhibition or AT(1) receptor blockade attenuated the IGF-I (10(-7) M) induced neonatal rat cardiac fibroblast growth in a concentration-dependent fashion (moexiprilat: 50+/-2%, enalaprilat: 31+/-2%, CV11974; 58+/-1%, all: 10(-7) M). Enalaprilat 181-192 angiotensin I converting enzyme Rattus norvegicus 0-3 11799091-2 2002 In the present study, we performed experiments to explore renal interstitial fluid concentrations of Ang I and Ang II further and to determine whether these levels are altered by acute arterial infusion of an ACE inhibitor (enalaprilat) or by volume expansion. Enalaprilat 224-235 angiotensin I converting enzyme Rattus norvegicus 209-212 11799091-6 2002 Intra-arterial infusion of enalaprilat (7.5 micromol/kg/min, n=5) for 120 minutes resulted in a significant decrease in mean arterial pressure (from 114+/-4 to 68+/-4 mm Hg) along with reductions in plasma and renal ACE activity (by -99% and -52%, respectively). Enalaprilat 27-38 angiotensin I converting enzyme Rattus norvegicus 216-219 11068029-5 2000 Angiotensin converting enzyme inhibitors, enalaprilat (3 microM), ramiprilat (1 microM) or lisinopril (1 microM), increased the bradykinin-induced renal vasodilation by 40% or more. Enalaprilat 42-53 angiotensin I converting enzyme Rattus norvegicus 0-29 10881050-5 2000 The specificity of the assay was demonstrated by the inhibition of ACE activity with 3 microM enalaprilat (MK-422). Enalaprilat 107-113 angiotensin I converting enzyme Rattus norvegicus 67-70 9886898-10 1998 The purified ACE were inhibited by enalaprilat and captopril, two potent competitive inhibitors of ACE and by EDTA, using Hippuryl-His-Leu as a substrate. Enalaprilat 35-46 angiotensin I converting enzyme Rattus norvegicus 13-16 10498289-4 1999 A less pronounced effect on cellular proliferation was seen with the ACE inhibitor enalaprilat. Enalaprilat 83-94 angiotensin I converting enzyme Rattus norvegicus 69-72 10498289-10 1999 These data show that the ACE inhibitors moexiprilat and enalaprilat inhibit Ang II induced proliferation of cardiac fibroblasts according to their relative potency of ACE inhibition in vitro. Enalaprilat 56-67 angiotensin I converting enzyme Rattus norvegicus 25-28 10498289-10 1999 These data show that the ACE inhibitors moexiprilat and enalaprilat inhibit Ang II induced proliferation of cardiac fibroblasts according to their relative potency of ACE inhibition in vitro. Enalaprilat 56-67 angiotensin I converting enzyme Rattus norvegicus 167-170 10560789-5 1999 Pulmonary inactivation of BK and conversion of Ang I were determined in conscious enalapril- or vehicle-treated rats before and after intravenous administration of the ACE inhibitor enalaprilat (MK-422, 10 mg/kg). Enalaprilat 182-193 angiotensin I converting enzyme Rattus norvegicus 168-171 10560789-9 1999 Acute ACE inhibition with MK-422 reduced BK inactivation to 42.0% +/- 2.7%. Enalaprilat 26-32 angiotensin I converting enzyme Rattus norvegicus 6-9 10444586-12 1999 Acute enalaprilat treatment decreased ACE activity in renal intermicrovillar clefts by 90% and in renal endosomes by 84%. Enalaprilat 6-17 angiotensin I converting enzyme Rattus norvegicus 38-41 10330262-11 1999 ACE and NEP participate in the degradation of BK since both enalaprilat and omapatrilat have potentiating effects on the t1/2 of BK. Enalaprilat 60-71 angiotensin I converting enzyme Rattus norvegicus 0-3 9886898-10 1998 The purified ACE were inhibited by enalaprilat and captopril, two potent competitive inhibitors of ACE and by EDTA, using Hippuryl-His-Leu as a substrate. Enalaprilat 35-46 angiotensin I converting enzyme Rattus norvegicus 99-102 9673444-6 1998 Angiotensin-converting enzyme inhibition was produced in vitro by incubation of enalaprilat or perindoprilat with human serum or cell membranes from rat heart. Enalaprilat 80-91 angiotensin I converting enzyme Rattus norvegicus 0-29 9673422-2 1998 Previous work has shown that enalaprilat, an inhibitor of angiotensin-converting enzyme (ACE), potentiated the actions of alpha 1-adrenoceptor antagonists; it was hypothesized that angiotensin II (AngII) modulated the activity of alpha 1-adrenoceptors. Enalaprilat 29-40 angiotensin I converting enzyme Rattus norvegicus 58-87 9673422-2 1998 Previous work has shown that enalaprilat, an inhibitor of angiotensin-converting enzyme (ACE), potentiated the actions of alpha 1-adrenoceptor antagonists; it was hypothesized that angiotensin II (AngII) modulated the activity of alpha 1-adrenoceptors. Enalaprilat 29-40 angiotensin I converting enzyme Rattus norvegicus 89-92 12013484-0 1996 Studies on the interactions between the angiotensin converting enzyme inhibitor enalaprilat and calcium antagonists in rats. Enalaprilat 80-91 angiotensin I converting enzyme Rattus norvegicus 40-69 9683926-7 1998 The angiotensin-converting enzyme (ACE) inhibitor, enalaprilat (130 nM), reduced BK degradation at all flow rates. Enalaprilat 51-62 angiotensin I converting enzyme Rattus norvegicus 4-33 9683926-7 1998 The angiotensin-converting enzyme (ACE) inhibitor, enalaprilat (130 nM), reduced BK degradation at all flow rates. Enalaprilat 51-62 angiotensin I converting enzyme Rattus norvegicus 35-38 9321871-7 1997 Intravenous pretreatment with the angiotensin-converting enzyme (ACE) inhibitor enalaprilate (0.7 mg/kg) or the angiotensin II-receptor antagonist losartan (10 mg/kg) altered the response to hypovolemia to a transient one, and alkaline secretion returned to the control level within 40-50 min. Enalaprilat 80-92 angiotensin I converting enzyme Rattus norvegicus 34-63 9321871-7 1997 Intravenous pretreatment with the angiotensin-converting enzyme (ACE) inhibitor enalaprilate (0.7 mg/kg) or the angiotensin II-receptor antagonist losartan (10 mg/kg) altered the response to hypovolemia to a transient one, and alkaline secretion returned to the control level within 40-50 min. Enalaprilat 80-92 angiotensin I converting enzyme Rattus norvegicus 65-68 9331154-0 1997 ACE inhibition by enalaprilate stimulates duodenal mucosal alkaline secretion via a bradykinin pathway in the rat. Enalaprilat 18-30 angiotensin I converting enzyme Rattus norvegicus 0-3 9322979-2 1997 In addition, we evaluated the effect of angiotensin-converting enzyme (ACE) inhibition with enalaprilat treatment (10 mg/kg I.V.) Enalaprilat 92-103 angiotensin I converting enzyme Rattus norvegicus 71-74 12013484-2 1996 METHODS: The interactions between the ACE inhibitor enalaprilat and the calcium antagonists diltiazem, cinnarizine, felodipine and verapamil were studied in anesthetized rats for effects on blood pressure and in isolated perfused rat tail arteries for effects at alpha1-adrenoceptors. Enalaprilat 52-63 angiotensin I converting enzyme Rattus norvegicus 38-41 7503796-7 1995 When 125I-Ang I was perfused in the presence of ACE inhibitors (enalaprilat, ramiprilat) in concentrations up to 130 microM, the formation of Ang II was only partially inhibited (approximately 50%). Enalaprilat 64-75 angiotensin I converting enzyme Rattus norvegicus 48-51 8394914-6 1993 Enalaprilat (6 x 10(-8) M), an inhibitor of ACE, also enhanced BK-induced contraction. Enalaprilat 0-11 angiotensin I converting enzyme Rattus norvegicus 44-47 7700846-1 1994 Objectives of this study were to determine if aerosolized bradykinin causes bronchoconstriction in anesthetized, mechanically ventilated rats, and if pretreatment with enalaprilat, an inhibitor of angiotensin-converting enzyme (ACE), or phosphoramidon, an inhibitor of endopeptidase 24.11 (EP 24.11), alters the response. Enalaprilat 168-179 angiotensin I converting enzyme Rattus norvegicus 197-226 1282072-7 1992 Potencies of all these agonists were not significantly different (P > 0.05) when experiments were carried out in the presence of the neutral endopeptidase inhibitor, phosphoramidon, and the kininase II inhibitor, enalaprilat (both 1 microM). Enalaprilat 216-227 angiotensin I converting enzyme Rattus norvegicus 193-204 1363432-7 1992 Enalaprilat (an inhibitor of kininase II) blocked the formation of BK1-7 and BK1-5 and increased the recovery of BK4-9. Enalaprilat 0-11 angiotensin I converting enzyme Rattus norvegicus 29-40 1363433-8 1992 When kininase II was inhibited with enalaprilat, the recovery of bradykinin increased from 10 to 43% in SHR and from 23 to 58% in NWR, whereas about 90% of the higher bradykinin homologues were recovered in both SHR and NWR. Enalaprilat 36-47 angiotensin I converting enzyme Rattus norvegicus 5-16 1649762-3 1991 [3H]Ramiprilat binding was completely inhibited by specific inhibitors of ACE: ramiprilat, ramipril, enalaprilat, enalapril and captopril. Enalaprilat 101-112 angiotensin I converting enzyme Rattus norvegicus 74-77 1330581-5 1992 Enalaprilat inhibited the activity of purified ACE, whereas KPP was completely devoid of such an effect. Enalaprilat 0-11 angiotensin I converting enzyme Rattus norvegicus 47-50 1317125-8 1992 In rats fed normal chow, infusion of enalaprilat for 1 h abolished plasma ACE activity but decreased renal ACE activity by only 58%. Enalaprilat 37-48 angiotensin I converting enzyme Rattus norvegicus 74-77 1317125-8 1992 In rats fed normal chow, infusion of enalaprilat for 1 h abolished plasma ACE activity but decreased renal ACE activity by only 58%. Enalaprilat 37-48 angiotensin I converting enzyme Rattus norvegicus 107-110 1741993-8 1991 The acute blood pressure decrease initiated in normotensive rats by an ACE-inhibitor (enalaprilat) was abolished in medullectomized rats, indicating an interaction between the renin-angiotensin and the renomedullary antihypertensive systems. Enalaprilat 86-97 angiotensin I converting enzyme Rattus norvegicus 71-74 1331222-4 1992 The ACE inhibitor, enalaprilat, was infused i.c.v. Enalaprilat 19-30 angiotensin I converting enzyme Rattus norvegicus 4-7 1315824-1 1992 OBJECTIVE AND DESIGN: This study was designed to test whether previous work, which showed that the angiotensin converting enzyme (ACE) inhibitor enalaprilat potentiated the alpha 1-adrenoceptor antagonist activity of doxazosin in isolated rat tail arteries, could be extended to demonstrate a synergistic hypotensive effect of these two drugs. Enalaprilat 145-156 angiotensin I converting enzyme Rattus norvegicus 99-128 1315824-1 1992 OBJECTIVE AND DESIGN: This study was designed to test whether previous work, which showed that the angiotensin converting enzyme (ACE) inhibitor enalaprilat potentiated the alpha 1-adrenoceptor antagonist activity of doxazosin in isolated rat tail arteries, could be extended to demonstrate a synergistic hypotensive effect of these two drugs. Enalaprilat 145-156 angiotensin I converting enzyme Rattus norvegicus 130-133 1652204-2 1991 This increase was abolished by the angiotensin-converting enzyme (ACE) inhibitor, enalaprilat, given in vivo. Enalaprilat 82-93 angiotensin I converting enzyme Rattus norvegicus 35-64 1652204-2 1991 This increase was abolished by the angiotensin-converting enzyme (ACE) inhibitor, enalaprilat, given in vivo. Enalaprilat 82-93 angiotensin I converting enzyme Rattus norvegicus 66-69 2154128-4 1990 Administration of an ACE inhibitor, enalaprilat, given in vivo returned basal prostanoid production by isolated glomeruli of BUO rats to levels seen in glomeruli of control rats. Enalaprilat 36-47 angiotensin I converting enzyme Rattus norvegicus 21-24 1708041-1 1991 Using paired isolated perfused rat tail artery segments, it was found that enalaprilat, an ACE inhibitor, augmented 1.6-fold the contractile responses to phenylephrine (PE), an alpha 1-adrenoceptor agonist. Enalaprilat 75-86 angiotensin I converting enzyme Rattus norvegicus 91-94 1709269-3 1991 However other inhibitors of these two enzymes, kelatorphan for endopeptidase-24.11 and enalaprilat for angiotensin I converting enzyme were essentially inactive, indicating that both enzymes are probably not involved in the degradation of endogenous substance P. Instead, the non-additive protecting effect of bacitracin, captopril and thiorphan might be due to the blockade of some "bacitracin-sensitive enzyme" playing a key role in the catabolism of SP within the rat spinal cord. Enalaprilat 87-98 angiotensin I converting enzyme Rattus norvegicus 103-134